title: Food and Drug Administration Adverse Event Reports of Retinal Vascular Occlusions Associated With Phosphodiesterase Type 5 Inhibitor Use.
authors.affiliation: Department of Ophthalmology, Northwell Health and Hofstra Northwell School of Medicine, Great Neck, New York.
authors.forename: Albert S
authors.initials: AS
authors.lastname: Li
authors.forename: Howard D
authors.initials: HD
authors.lastname: Pomeranz
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data*; D016208:Databases, Factual; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology; D006801:Humans; D058986:Phosphodiesterase 5 Inhibitors / Q000009:adverse effects*; D011358:Product Surveillance, Postmarketing; D011743:Pyrimidines / Q000009:adverse effects; D015356:Retinal Artery Occlusion / Q000139:chemically induced*; D012170:Retinal Vein Occlusion / Q000139:chemically induced*; D000068677:Sildenafil Citrate / Q000009:adverse effects; D000068581:Tadalafil / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration; D000069058:Vardenafil Dihydrochloride / Q000009:adverse effects
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D011743:Pyrimidines; D000069058:Vardenafil Dihydrochloride; D000068581:Tadalafil; D000068677:Sildenafil Citrate; C553414:avanafil